Slide 1: Full Year Results for the financial year ended 31 March 2015
Full Year Results for the financial year ended 31 March 2015 David Darling, CEO and ExecuCve Director
Slide 2: FY15 Highlights
02: FY15 HIGHLIGHTS Primary Focus On Execu>on Of US Market Strategy Strong Upli, in Launch of Second Strong Commercial Con?nued Investment Commercial Revenue Product, Cxbladder Progress in US into Growth Triage Reflects rollout of US Launched in NZ in late Increasing awareness, People, Intellectual s
Slide 3: Our Strategy
03: OUR STRATEGY Growth Strategy, Primarily Focused On The US Market OUR OFFER Delivering innovaCve soluCons for the early detecCon and beSer management of cancer Current focus on building a suite of Cxbladder diagnosCc tests, to help detect and manage bladder cancer Our tests are non-‐invasive, ac
Slide 4: Commercial Progress To Date: Expanding Cxbladder Product Offering
04: COMMERCIAL PROGRESS TO DATE Expanding Cxbladder Product Offering Building a ‘One Stop Shop’ • Launch of first Cxbladder product, Detect, in US in mid-‐2013 Offering of Cxbladder Tests • Launch of second Cxbladder product, Triage, in New Zealand in late 2014 with US launch planned for 2015. Cxbladd
Slide 5: Commercial Progress To Date: Early Stage Market Penetration
05: COMMERCIAL PROGRESS TO DATE Early Stage Market Penetra>on With Main Focus On US Increasing Our Market • Established commercial partnerships in US, New Zealand and Australia PenetraCon • Primary focus on the US, one of the world’s biggest healthcare markets • Strong penetraCon into NZ market • Co
Slide 6: Commercial Progress To Date: Growing Awareness and Credibility
06: COMMERCIAL PROGRESS TO DATE Growing Awareness and Credibility of Products Amongst Medical Community Investment into clinical • CompleCon of two large validaCon studies for Cxbladder with results supporCng clinical study findings performance validaCon studies, research and peer • Four peer-‐revie
Slide 7: Commercial Progress To Date: User Programmes Driving Trial And Adoption
07: COMMERCIAL PROGRESS TO DATE User Programmes Driving Trial And Adop>on Increasing Trial of Products by • Increasing number of User Programmes in US and other markets Targeted Urologists • Large scale User Programme for 2,000 paCents in partnership with Southern California Permanente Medical Group
Slide 8: US Market Update
08: US MARKET UPDATE Expanding Specialist Sales Team Focusing On Targeted Regions TARGETING THE US, ONE OF THE COMMERCIAL PROGRESS TO DATE WORLD’S LARGEST HEALTHCARE MARKETS Expanded specialist US sales team from four to Primary focus for Pacific Edge in the short to twelve personnel medium term Incr
Slide 9: Other Markets
09: OTHER MARKETS Good Progress In New Zealand; Iden>fied New Opportunity In SE Asia OTHER MARKETS COMMERCIAL PROGRESS TO DATE New Zealand: Commercial operaCons Good progress in New Zealand with increasing use including wholly owned laboratory of Cxbladder by urologists in public and private sector A
Slide 10: FY15 Summary Financial Performance
10: FY15 SUMMARY FINANCIAL PERFORMANCE Result Reflects Ongoing Investment into Growth Strategy Strong uplip in sales revenue reflecCng FY15 FY14 growing tracCon in US market and strong $NZ’000 $NZ’000 increase in commercial customer numbers Sales Revenue 1,900 145 Second year of funding from a $4.5 mi
Slide 11: FY15 Financial Position – Balance Sheet
11: FY15 FINANCIAL POSITION – BALANCE SHEET Investment into Commercialisa>on and US Rollout Cash and cash equivalents $7.82 million as at FY15 FY14 31 March 2015 $NZ’000 $NZ’000 Debt free with funding from capital and Cash, Cash Equivalents and 7,819 20,444 technology grants for commercialisaCon and
Slide 12: Strategic Opportunities For Growth
12: STRATEGIC OPPORTUNITIES FOR GROWTH TargeCng High Growth Over The Medium Term by CreaCng More Products and Building Sales in an Increasing Number of Markets • Development of suite of Cxbladder products More Products • IP over other cancer expressions with opportunity to develop specific diagnosCc
Slide 13: Outlook
13: OUTLOOK Another Year Of Significant Investment Into The Rapid Growth Of The Business The United States healthcare market • Expand sales force and enter new targeted sales regions remains primary focus and will be main • Increase the number of User Programmes and focus on converCng User Programmes
Slide 14: Board and Management
14: BOARD AND MANAGEMENT Providing The Experience and Capability to Deliver on Pacific Edge’s Growth Strategy MANAGEMENT TEAM GOVERNANCE Experienced and knowledgeable in the Board of Directors following areas: Experience in governance, finance, cancer research, Development and internaConal biotechnolo
Slide 15: Questions?
QUESTIONS? Pacific Edge FY15 Results PresentaCon
Slide 16: Contact details
www.pacificedge.co.nz www.cxbladder.com www.pacificedgedx.com David Darling Chief ExecuCve Officer Pacific Edge Limited Tel: +64 3 479 5802 Mobile: +64 21 797981 Email: dave.darling@pelnz.com Pacific Edge FY15 Results PresentaCon
Slide 17: Disclaimer
DISCLAIMER This results presentaCon has been prepared by Pacific Edge Limited (Pacific Edge) in relaCon to its full year results for the year ended 31 March 2015. Informa?on This presentaCon contains informaCon from Pacific Edge's Preliminary Consolidated Financial Statements for the year ended 31 Marc